Xinhua News Agency, Beijing, February 27 (Reporter Peng Yunjia) The National Health Insurance Administration's Pharmaceutical ** and Bidding and Procurement Guidance Center released on the 27th the situation of 26 pharmaceutical companies rated as "particularly serious" and "serious" in various provinces as of December 31, 2023, of which 22 pharmaceutical companies were rated "serious" and 4 pharmaceutical companies were rated "particularly serious".
The 4 pharmaceutical companies rated as "particularly serious" are Sichuan Beijukang Medical Devices, Sichuan Runzeyuan Medical Devices Co., Ltd., Zunyi Baiyi Pharmaceutical, Yunnan Jiye Pharmaceuticals, and 22 pharmaceutical companies rated as "serious", including Beijing Nengji Traditional Chinese Medicine Beverage ***, Taizhou Daai Medical Equipment***, Lianyungang Suchuang Medical Devices***, etc.
List of 26 untrustworthy pharmaceutical companies. (Official website of the National Health Insurance Administration).
Through the formulation of the credit evaluation catalogue list, the National Health Insurance Administration will include pharmaceutical commercial bribery, tax-related violations, monopolistic behaviors, improper behaviors, disruption of centralized procurement order, malicious violations of contracts and other behaviors contrary to honesty and credibility into the scope of pharmaceutical and procurement credit evaluation.
Based on factors such as the nature, circumstances, timeliness, and impact of the untrustworthy conduct, provincial-level centralized procurement institutions are to assess the untrustworthiness of pharmaceutical enterprises in the local bidding and procurement market as "general", "moderate", "serious", and "particularly serious", which are dynamically updated on a quarterly basis.
According to the credit rating of pharmaceutical enterprises, provincial-level centralized procurement institutions shall take measures such as reminding and warning in writing, relying on the centralized procurement platform to remind the purchaser of risk information, restricting or suspending the bidding of relevant drugs or medical consumables, and publicly disclosing information on untrustworthiness to the public. When the circumstances are particularly serious, the untrustworthy enterprise will face the risk of losing the centralized procurement market.
*:Xinhua.
Disclaimer: Huasheng** maintains neutrality in the statements and opinions in the text, and does not provide any express or implied guarantee for the accuracy, reliability or completeness of the content contained. The article is the author's personal opinion and should not be used as an investment basis. Readers should understand all the relevant investment risks in detail and take full responsibility for them. Some articles are submitted and published by online authors, and the copyright belongs to the contributing authors. The author shall be responsible for the authenticity and copyright of the article and **. Once a copyright dispute arises and the right holder raises an objection, Huasheng** will delete the corresponding content in accordance with the provisions of relevant laws and regulations. The liability for infringement shall be borne by the contributor, and the contributor shall be liable for compensation if the loss of Huasheng ** is caused thereby. If you have any objections to this article, please contact us 38160107 Change to @)qqcom。